PCN49 Disease Burden of Classical Hodgkin Lymphoma UNDER Current Treatment Pattern in China

Abstract

To estimate the disease burden of classical Hodgkin lymphoma (cHL) under current treatment pattern in China. A decision-analytic model was constructed to simulate the Chinese patients with cHL and the age and gender-matched Chinese general population over lifetime time horizon for the differences in overall survival, quality-adjusted life years (QALY), and lifetime direct medical costs. Literature search was conducted to identify appropriate evidence to estimate the model variables. Base case analysis and sensitivity analysis were conducted for the point estimations and uncertainty of the disease burden of cHL. The Chinese cHL patients were associated with reduced average overall survival by 13.453 years (27.317 years vs. 40.770 years), reduced average QALY by 12.449 QALY (24.448 QALY vs. 36.897 QALY), and increased average life-time direct medical costs by ¥262,040 (¥451,395 vs. ¥189,355) under current treatment pattern. The reduced QALY associated with cHL was highly sensitive to disease recurrence after the treatment for early stage of cHL (change: -15.349 QALY), patient age (change: 4.561 QALY), and quality of life of early stage of cHL (change: 2.106QALY). The lifetime direct medical costs associated with cHL was highly sensitive to the disease recurrence after the treatment for early stage of cHL (change: ¥637,508), treatment effect of pembrolizumab (change: ¥-303,899), mortality of progressive disease (change: ¥-243,770), and patient weight (change: ¥115,609). The probabilistic sensitivity analysis with 5,000 Monte Carlo simulations estimated the median and 95% credible interval of reduced QALY ( -11.580 QALY, -21.642 to -5.442 QALY) and increased lifetime direct medical costs (¥275,349, ¥-2,296 to ¥1,200,886). The disease burden of cHL in China was characterized with reduced overall survival, reduced QALY, and increased medical costs that were sensitive to patient demographics, disease recurrence, quality of life, treatment effect of pembrolizumab, and the mortality of progressive disease.